Is MOTS-c Legal in Virginia? Drug Status and State Rules

HealthRX.com

MOTS-c is not on any FDA list for compounding in Virginia

Print or save as PDF

See the public record for MOTS-c

  • FDA approval / None; no approved product contains it [1]
  • Compounding bulk lists / Not listed in any category [2][3][4]
  • FDA advisory committee / Advised adding it, 23 July 2026; non-binding [7]
  • HHS draft policy / Enforcement discretion for MOTS-c acetate; not binding [5][6]
  • Human exposure data / None found by FDA, any route [1]
  • WADA / Prohibited at all times, S4.4.1 [8]

Is MOTS-c an approved drug?

No. MOTS-c is not an FDA-approved drug and is not a component of one; FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no product authorised by the European Medicines Agency [1]. It is a 16-amino-acid peptide encoded in mitochondrial DNA [1][9].

Is it on FDA's compounding lists?

FDA's rules for state-licensed pharmacies and physicians set three routes for a bulk substance used in compounding: it complies with an applicable USP or NF monograph, it is a component of an FDA-approved drug, or it appears on FDA's list of bulk substances that can be used in compounding [4]. MOTS-c fits none of those routes [1][2][4]. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated 14 May 2026) and is not on FDA's list for outsourcing facilities (updated 21 March 2025) [2][3][4].

FDA's page on bulk substances that may present significant safety risks lists MOTS-c in its 'nominated but withdrawn' table, which holds substances previously in category 2 whose nominators withdrew them. FDA's stated concern is that injectable peptides may pose immunogenicity risk from aggregation and impurities. Removal from category 2 was not a finding that MOTS-c is safe [10].

What changed in 2026?

FDA's Pharmacy Compounding Advisory Committee reviewed MOTS-c free base and acetate on 23 July 2026 and voted in favour of adding it to FDA's list of bulk substances that can be used in compounding, against FDA staff's recommendation [7][5]. That advice is non-binding, MOTS-c is not on the list, and listing takes formal rulemaking [7][5]. FDA staff had argued against listing because MOTS-c is not well characterised, has no animal toxicity studies, and approved treatments exist for obesity and osteoporosis, two of the nominated uses [1].

HHS's draft enforcement-discretion policy, filed 28 October 2026 as Federal Register document 2026-22192, names MOTS-c among six peptides and covers MOTS-c acetate given subcutaneously or intramuscularly [5][6]. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with it where the policy's conditions are met [5][6]. Those conditions include a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [5][6]. The notice states the draft does not establish rights for any person and is not binding on HHS or the public [5]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [5].

Does a Virginia prescription change that?

The federal limits on bulk substances apply to the pharmacy or physician doing the compounding. A prescription by itself is not one of the three routes a bulk substance must fit [4]. Under the HHS draft, a patient-specific prescription is one condition among several, and the draft is not binding [5][6].

Questions worth asking

Choose the questions you want to keep

Is MOTS-c prohibited in sport?

WADA names MOTS-c in S4.4.1, the metabolic-modulator class covering AMPK activators, and prohibits it at all times, in and out of competition [8][11]. It is on WADA's 2026 List and on the tracked-changes version of the 2027 List [8][11].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. Which best describes MOTS-c's status according to the article?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Can you buy MOTS-c as a prescription in Virginia?
MOTS-c is not an FDA-approved prescription drug and is absent from both of FDA's lists of bulk substances permitted for compounding [1][2][3]. The HHS draft policy would describe limited enforcement discretion for certain MOTS-c acetate injections where its conditions are met; it would not make MOTS-c FDA-approved or add it to FDA's list [5][6].
Did the July 2026 advisory committee vote make MOTS-c legal to compound?
No. The recommendation is non-binding and FDA staff had recommended against listing it. MOTS-c is not on FDA's list of bulk substances that can be used in compounding, and adding it takes formal rulemaking [1][7][5].
Has MOTS-c been given to people?
FDA found no clinical study in which MOTS-c was given to humans by any route. Human studies measured the body's own MOTS-c, for example the rise after exercise [1][12][13].
Show all 13 referencesHide references
  1. U.S. Food and Drug Administration.
  2. U.S. Food and Drug Administration.
  3. U.S. Food and Drug Administration.
  4. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
  5. Official web page.
  6. Official web page.
  7. U.S. Food and Drug Administration.
  8. World Anti-Doping Agency.
  9. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
  10. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  11. World Anti-Doping Agency.
  12. Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
  13. von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
Clinical research record review in a laboratory setting
Clinical research record review in a laboratory setting. Image: HealthRX.com clinical research illustration